1. Merck leaps into COVID vaccine race — Evofem Biosciences gets FDA approval for new non-hormonal contraceptive — Sanofi sells $13 billion stake in Regeneron — See more on our front page news Stay updated with the latest pharma-related coronavirus news on our new page
    Dismiss Notice
  2. Think you have witnessed fraud?Ask a Whistleblower Attorney -- a chance to discuss whistleblower-related legal issues with practicing whistleblower attorneys.
    Dismiss Notice

Women's Health Guaranteed Positions

Discussion in 'Allergan' started by anonymous, Aug 18, 2019 at 9:09 PM.

Tags: Add Tags
  1. anonymous

    anonymous Guest

    Since you are so sharp are you aware the Relugolix was studied with estradiol and a progestin. Efficacy is there, hot flashes less than orilissa, bone loss comparable to placebo. I guess when they changed the message on type of birth control to use with Orilissa at the meeting last month you did not question why. LoLo contains 2 hormones: norethindrone (a progestin) and ethinyl estradiol (an estrogen).
     

  2. anonymous

    anonymous Guest


    Whoa! Battle of the lunch caterers! You guys are flexing some serious brain power here.

    Now, can either of you tell me what’s on a Reuben sandwich?
     
  3. anonymous

    anonymous Guest

    Been in pharma for over 20 years and yet to work a 40 hour week. I would be glad to research what is on a Reuben and get back to you.
     
  4. anonymous

    anonymous Guest

    I’m sorry, who is Myovant Sciences compared to Abbvie?! Hahahahaha! Trust me, we talked about everything that we need to know at our last meeting. We’re still gonna beat you out in the field. Lol!! Get ready!!
     
  5. anonymous

    anonymous Guest

    Dummy rye bread Russian dressing, sauerkraut, corned beef and Swiss cheese grilled.
     
  6. anonymous

    anonymous Guest


    Wow, a battle royal!!! Now, who can carry more Starbucks drinks at once?!? ANNNNDD... GO!
     
  7. anonymous

    anonymous Guest

    Myovant Science developed the drug. Takeda will market it. Just think Orilissa is on track to hit 64 million for 2019. Wow that is quite an accomplishment.
     
  8. anonymous

    anonymous Guest

    While a Reuben is certainly delicious, who can tell me what a Rachel is?

    C’mon Lunchables! I’m getting hungry.
     
  9. anonymous

    anonymous Guest

    Goodbye to WH reps. It's was nice knowing you! See ya Taytulla and Liletta!!!!!
     
  10. anonymous

    anonymous Guest

    That is a sad testimony to The Forest Touch. It was such a great Division with so much promise until the Forest Management team took over. Replacing half the tenured Reps with clueless ones from PC roles right after Liletta launch was a baffling move and it just went down hill from there. They gave us CR and SB those people speak for themselves. They told us that Linzess and Viberzi would catapult WH into the stratosphere.....6 weeks before they took it back out of our bags. Those were the days. Now who knows what they’ve been up to only the dregs are left. They were like locust who devoured and departed with no thought or care. After all it’s The Forest Way
     
  11. Mo Cowbell

    Mo Cowbell Guest

    a lot of Abbvie reps sold women’s health when they were Solvay. The Abbvie legacy reps are morons.
     
  12. anonymous

    anonymous Guest

    Morons like me.
     
  13. anonymous

    anonymous Guest

    abbvie reps will be toast. Realignment is happening so we can carry on when we inherit Orlissa. We are multi-product specialists, they are one trick ponies that can’t get their own product going (not blaming them, it’s just what it is). We will be good and we will take over probably half way into the new year and sell their fibroid indication like we were supposed have with Esmya. Hope I didn’t hurt any feelings...
     
  14. anonymous

    anonymous Guest

    Good luck with that theory! Allergan has been trying to dump WH for years now we are an asset to the company.
     
  15. anonymous

    anonymous Guest

    I am interviewing for a position as an outsider. I keep hearing that the company is putting WH reps in these positions and not to bother because the company does not want to pay the severance. What information is out there about this?
     
  16. anonymous

    anonymous Guest

    Don't waste your time. All we have is Lo lo. Taytulla sucks and Liletta is doing terrible. WH was once great. "THE PLACE TO BE" they said.
     
  17. anonymous

    anonymous Guest

    Is Liletta getting a new 6 year indication soon? And I thought there was a new exciting inserter coming out also?? It can't be doing that bad????
     
  18. anonymous

    anonymous Guest

    What is going to happen with Esmya? Liletta getting a new 6 year indication? New inserter coming?
     
  19. anonymous

    anonymous Guest

    Liletta 6 next year
     
  20. anonymous

    anonymous Guest

    haha. They were telling us the 7 year indication was just around the corner when we launched it.